Exp Clin Endocrinol Diabetes 2004; 112(8): 435-439
DOI: 10.1055/s-2004-821189
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Interleukin-6 (IL-6) and IGF-IGFBP System in Children and Adolescents with Type 1 Diabetes Mellitus[*]

A. Wędrychowicz1 , H. Dziatkowiak1 , K. Sztefko2 , A. Wędrychowicz3
  • 1Department of Pediatric Endocrinology, Polish-American Children's Hospital, Jagiellonian University, Kraków, Poland
  • 2Department of Clinical Biochemistry, Polish-American Children's Hospital, Jagiellonian University, Kraków, Poland
  • 3Department of Pediatrics, Gastroenterology and Nutrition, Polish-American Children's Hospital, Jagiellonian University, Kraków, Poland
Further Information

Publication History

Publication Date:
16 September 2004 (online)

Preview

Abstract

Background: Some studies suggest that IL-6 is connected with glucose metabolism and insulin action, so like IGF-IGFBPs system it could play the role in diabetes etiopathogenesis.

Aim: The aim of the study was therefore to test the hypothesis that in children and adolescents IL-6 is of importance for the etiopathogenesis of diabetes mellitus type 1 and that IL-6 is connected with carbohydrate metabolism and IGF-IGFBPs action.

Methods: There were 49 patients with type 1 diabetes: 10 persons at onset diabetes and 39 with disease lasted at least 1 year and 33 age-matched healthy children included into the study. Serum IGF-I concentrations were measured by RIA; IGFBP-1 and IGFBP-2 by IRMA and IL-6 concentrations using quantitative ELISA immunoassays. HbA1c was measured by HPLC method. Multiple regression, ANOVA, and Student's t-test were used for statistical analysis.

Results: IL-6 and IGF-I, IGFBP-1 and IGFBP-2 levels did not differ statistically significant between diabetic patients and controls. IL-6 concentrations were statistically higher at onset diabetes than in diabetic patients with long-term disease. IL-6 did not correlate with IGF-I and its binding proteins - 1 and - 2 in examined groups. At onset of disease IL-6 correlated with insulin requirement. There were not found correlations between IL-6 and HbA1c in diabetic groups. IGF-I positively correlated with age and growth in both groups and with IGFBP-2 in diabetic patients. IGFBP-2 correlated negatively with BMI in all examined groups.

Conclusions: IL-6 might play a significant role in type 1 diabetes mellitus etiopathogenesis. It seems that IL-6 does not regulate IGF-IGFBP system in diabetic children and adolescents or IL-6 maybe cooperate with IGF-I, but their significant dependence on insulin action influences their mutual relationships.

1 A preliminary version of this study was presented at ISPAD 2001, Sienna, Italy

References

  • 1 Bendtzen K, Buschard K, Diamant M, Horn T, Svenson M. Possible role of IL-1, TNF-alpha, and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease.  Lymphokine Res. 1989;  8 335-340
  • 2 Boyne M S, Thame M, Bennett F I, Osmaond C, Miel J P, Forrester T E. The relationship among circulating insulin-like growth factor (IGF)-I, IGF-binding proteins-1 and -2, and birth anthropometry: a prospective study.  J Clin Endocrinol Metab. 2003;  88 1687-1691
  • 3 Cavallo M G, Pozzilli P, Bird C, Wadhwa M, Meager A, Visalli N, Gearing A J, Andreani D, Thorpe R. Cytokines in sera from insulin-dependent diabetic patients at diagnosis.  Clin Exp Immunol. 1991;  86 256-259
  • 4 Cole T J, Donnet M L, Stanfield J P. Weight-for-height indices to assess nutritional status-a new index on a slide-rule.  Am J Clin Nutr. 1981;  34 1935-1943
  • 5 De Benedetti F. Cytokines and Growth Impairment Associated with Chronic Inflammation.  Horm Res. 2000;  53 6
  • 6 De Benedetti F, Meazza C, Martini A. Role of interleukin-6 in growth failure: an animal model.  Horm Res. 2002;  58 24-27
  • 7 De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis.  Endocrinology. 2001;  142 4818-4826
  • 8 de Martino M, Galli L, Chiarelli F, Verrotti A, Rossi M E, Bindi G, Galluzzi F, Salti R, Vierucci A. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth-factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection.  Clin Immunol. 2000;  94 212-218
  • 9 Eckstein F, Pavicic T, Nedbal S, Schmidt C, Wehr U, Rambeck W, Wolf E, Hoeflich A. Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density in the absence and presence of growth hormone/IGF-I excess in transgenic mice.  Anat Embryol (Berl). 2002;  206 139-148
  • 10 Fernandez-Celemin l, Thissen J P. Interleukin-6 stimulates hepatic insulin-like growth factor binding protein-4 messenger ribonucleic acid and protein.  Endocrinology. 2001;  142 241-248
  • 11 Froesch E R, Mehboob A, Hussain A, Zapf J. Insulin growth factor I: Physiology, metabolic effects and clinical uses.  Diab Met Rev. 1996;  12 195-215
  • 12 Frystyk J, Bek T, Flyvbjerg A, Skjaerbaek C, Orskov H. The relationship between the circulating IGF system and the presence of retinopathy in type 1 diabetic patients.  Diabet Med. 2003;  20 269-276
  • 13 Geerlings S E, Brouwer E C, Van Kessel K C, Gaastra W, Stolk R P, Hoepelman A I. Cytokine secretion is impaired in women with diabetes mellitus.  Eur J Clin Invest. 2000;  30 995-1001
  • 14 Granot D, Synder M. Glucose induces cAMP-independent growth-related changes in stationary cells of Saccharomyces cerevisiae.  Proc Natl Acad Sci USA. 1991;  88 5724-5728
  • 15 Jeschke M G, Barrow R E, Herndon D N. Insulin-like growth factor I plus insulin-like growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children.  Ann Surg. 2000;  231 246-252
  • 16 Juul A, Bang P, Hertel N T. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.  J Clin Endocrinol Metab. 1994;  78 744-752
  • 17 Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus.  Acta Diabetol. 1999;  36 67-72
  • 18 Katsanos K H, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos E V. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.  Growth Horm IGF Res. 2001;  11 364-367
  • 19 Kołaczyński J W, Caro J F. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks.  Ann Intern Med. 1994;  120 47-55
  • 20 Kopczyńska-Sikorska J. Normy w pediatrii. 1st ed. Warszawa; PZWL 1996: 11-64
  • 21 Krsek M, Skrha J, Sucharda P, Justova V, Lacinova Z. Changes in IGF-I levels and its binding proteins in diabetes mellitus and obesity.  Cas Lek Ces. 2003;  142 216-219
  • 22 Lelbach A, Scharf J G, Ramadori G. Regulation of insulin-like growth factor-I and insulin-like growth factor binding protein-1, -3, -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6.  J Hepatol. 2001;  35 558-567
  • 23 Le Roith D. Insulin-like growth factors.  N Engl J Med. 1997;  336 633-640
  • 24 Lewitt M S, Denyer G S, Cooney G J, Baxter R C. Insulin-like growth factor-binding protein-1 modulates blood glucose levels.  Endocrinology. 1991;  129 2254-2257
  • 25 McCarty M F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol, and pentoxifylline.  Med Hypotheses. 1999;  52 465-477
  • 26 Niedźwiedzka A, Dziatkowiak H, Sztefko K. IGF-I and its binding proteins in children and adolescents with IDDM.  Horm Res. 1999;  51 95
  • 27 Niedźwiedzka A, Dziatkowiak H. IGF-I and its binding proteins 1 and 3 in adolescents with IDDM and diabetic complications.  Horm Res. 2000;  53 61
  • 28 Nishimura F, Takahashi K, Kurihara M, Takashiba S, Murayama Y. Peridontal disease as a complication of diabetes mellitus.  Ann Peridontol. 1998;  3 20-29
  • 29 Ono S, Ichikura T, Mochizuki H. The pathogenesis of the systemic response syndrome and compensatory response syndrome following surgical stress.  Nippen Gela Galkoi Zasshi. 2003;  104 499-505
  • 30 Pickup J C, Chusney G D, Thomas S M, Burt D. Plasma interleukin-6, tumor necrosis factor alpha, and blood cytokine production in type 2 diabetes.  Life Sci. 2000;  67 291-300
  • 31 Reiter E O, Rosenfeld R G. IGFs and its binding proteins. Greenspan F, Strewler G Basic and Clinical Endocrinology. Stanford, CT; Appleton and Lange 1997: 1437-1453
  • 32 Rieu M, Binoux M. Serum levels of insulin-like growth factor (IGF) and IGF binding protein in insulin-dependent diabetics during an episode of severe metabolic decompensation and recovery phase.  J Clin Endocrinol Metab. 1985;  60 781-785
  • 33 Sandler S, Bendtzen K, Eizirik D L, Welsh M. Inerleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro.  Endocrinology. 1990;  126 1288-1294
  • 34 Soop M, Duxbury H, Agwunobi A O, Gibson J M, Hopkins S J, Childs Ch, Cooper R G, Maycock P, Little R A, Carlson G L. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans.  Am J Physiol Endocrinol Metab. 2002;  282 1278-1285
  • 35 Strasser-Vogel B, Blum W F, Past R. Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment.  J Clin Endocrinol Metab. 1995;  80 1207-1213
  • 36 Street M E, de'Angelis G L, Camacho-Huebner C, Savage M O, Fornaroli F, Bernasconi S, Giovannelli G. Interleukin-6 (IL-6) levels and the IGF-IGFBP system in chronic inflammatory bowel disease (CIBD) in childhood.  Horm Res. 2000;  53 64
  • 37 Street M E, Miraki-Mound F, Sanderson I R, Savage M O, Giovannelli G, Bernasconi S, Camacho-Huebner C. Interleukin (IL)-1 b and IL-6 modulate insulin-like growth factor binding protein (IGFBP) secretion in Caco-2 Cells.  Horm Res. 2000;  53 64
  • 38 Suikkari A M, Koivisto V A, Rutanen E M, Yki-Jarivinen H, Karonen S L, Seppala M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein.  J Clin Endocrinol Metab. 1988;  66 266-272
  • 39 van den Beld A W, Blum W F, Pols H A, Grobbee D E, Lamberts S W. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men.  Eur J Endocrinol. 2003;  148 627-634
  • 40 Wędrychowicz A, Stopyrowa J, Fyderek K, Mieżyński W. Serum and stool interleukin 6 in active and inactive ulcerative colitis in children.  Pediatria Współczesna. 2000;  3 165-169

1 A preliminary version of this study was presented at ISPAD 2001, Sienna, Italy

M. D., Ph.D. Anna Wędrychowicz

Polish-American Children's Hospital

ul. Wielicka 265

30-663 Kraków

Poland

Phone: + 48126581277

Fax: + 48 1 26 58 10 05

Email: miniedzw@cyf-kr.edu.pl